Hepion Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 21, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 21, 2024
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Preferred Stock · Additional Paid in Capital · Accumulated other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock | ||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||
| Balance at December 31, 2023 | 85,581 | $855,808 | 1,688 | $839,320 | 4,818,733 | $482 | $230,291,362 | $(78,779) | $(224,627,386) | $7,280,807 |
| Net loss | — | — | — | — | — | — | — | — | (2,853,806) | (2,853,806) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | 87,979 | — | 87,979 |
| Stock-based compensation expense | — | — | — | — | — | — | 705,770 | — | — | 705,770 |
| Warrant exercises, net | — | — | — | — | 654,393 | 65 | 2,300,624 | — | — | 2,300,689 |
| March 31, 2024 | 85,581 | 855,808 | 1,688 | 839,320 | 5,473,126 | 547 | 233,297,756 | 9,200 | (227,481,192) | 7,521,439 |
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Preferred Stock · Additional Paid in Capital · Accumulated other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock | ||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||
| Balance at December 31, 2022 | 85,581 | $855,808 | 1,801 | $840,320 | 3,811,481 | $381 | $223,950,940 | $(90,168) | $(175,701,344) | $49,855,937 |
| Net loss | — | — | — | — | — | — | — | — | (13,259,921) | (13,259,921) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | 19,353 | — | 19,353 |
| Stock-based compensation expense | — | — | — | — | — | — | 537,123 | — | — | 537,123 |
| Conversion of Series C to common | — | — | (1) | (1,000) | 1 | — | 1,000 | — | — | — |
| Balance at March 31, 2023 | 85,581 | 855,808 | 1,800 | 839,320 | 3,811,482 | 381 | 224,489,063 | (70,815) | (188,961,265) | 37,152,492 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.